Is Dark Chocolate Good for Fatty Liver?

Dark chocolate and fatty liver disease is a topic attracting growing interest, with emerging research suggesting that the flavanols in high-cocoa chocolate may offer modest liver benefits. Fatty liver disease, now more precisely termed metabolic dysfunction-associated steatotic liver disease (MASLD), affects a significant proportion of UK adults and is closely linked to obesity and type 2 diabetes. This article examines what the current evidence says about cocoa and liver health, how much dark chocolate is reasonable, which other foods support liver function, and what UK clinical guidance recommends for managing this condition.

Is dark chocolate actually good for a fatty liver?

Dark chocolate may offer modest liver benefits due to its cocoa flavanol content, but it is not a medicine or treatment for fatty liver disease and should not replace medical advice.

Dark chocolate, consumed in small amounts, may offer modest liver benefits for some people with fatty liver disease, though it is not a treatment and should not replace medical advice.

The umbrella term for fat accumulation in the liver is steatotic liver disease (SLD). The most common form in people without significant alcohol use is metabolic dysfunction-associated steatotic liver disease (MASLD), which is closely linked to obesity, type 2 diabetes and metabolic syndrome.^[2][3] NHS materials and many UK clinicians may still use the older term non-alcoholic fatty liver disease (NAFLD); both terms refer to the same condition. MASLD affects a significant proportion of adults in the UK. Alcohol-related steatosis is a separate condition and is not covered by the research discussed on this page.

The potential benefit of dark chocolate comes primarily from its high cocoa content, which is rich in flavanols, a class of plant-based antioxidants. These compounds have been studied for their possible ability to reduce oxidative stress and inflammation, both of which are thought to play a role in the progression of fatty liver disease, though the evidence remains preliminary. Milk chocolate and white chocolate generally contain lower levels of flavanols and more added sugar; saturated fat content varies considerably between products and brands, so checking the label is advisable.

Dark chocolate is not a medicine and carries no MHRA authorisation for any health condition. Any potential benefit is nutritional rather than therapeutic. People managing fatty liver disease should discuss dietary changes with their GP or a registered dietitian rather than self-prescribing foods based on emerging research. The British Liver Trust and the NHS NAFLD condition page both provide reliable patient-facing information on this condition.

What does the evidence say about cocoa and liver health?

Cocoa flavanols show biological plausibility for liver support, but current evidence from small trials is preliminary and insufficient to support firm clinical recommendations for MASLD.

Research suggests that cocoa flavanols may have beneficial effects on markers of liver health in people with fatty liver disease, though the evidence is not yet strong enough to support firm clinical recommendations. Several small clinical trials and animal studies have examined the effects of cocoa-derived compounds on liver function, with broadly encouraging but preliminary results.

One mechanism under investigation, primarily from preclinical and early human studies, involves the possible ability of flavanols to influence the absorption of dietary fat and glucose in the gut, which may reduce the metabolic load on the liver. Flavanols have also been studied for potential effects on nitric oxide production and intrahepatic blood flow, though these findings are largely exploratory. Their antioxidant properties may help reduce oxidative stress that contributes to liver cell damage. These mechanisms require confirmation in larger, well-designed human trials before conclusions can be drawn.

A randomised controlled trial published in the journal Gut (Hernandez-Guerra et al., 2010) examined the effects of dark chocolate on portal hypertension in patients with established cirrhosis and found a more favourable postprandial haemodynamic response compared with white chocolate. It is important to note that this study involved patients with advanced cirrhosis rather than early-stage MASLD, and the sample size was small. The findings cannot be directly generalised to people with MASLD or early fatty liver disease.

Larger, well-designed randomised controlled trials specifically in people with MASLD, measuring outcomes such as liver fat by MRI, liver enzyme levels (ALT and AST) and fibrosis markers, are needed before cocoa can be formally recommended as part of liver disease management. The overall picture is one of cautious optimism: cocoa flavanols appear biologically plausible as a liver-supportive nutrient, but the current evidence does not justify consuming dark chocolate in large quantities or as a substitute for proven lifestyle interventions.

How much dark chocolate is safe if you have fatty liver disease?

No clinical guideline specifies a daily amount; small portions of minimally processed dark chocolate with at least 70 per cent cocoa are unlikely to be harmful within a balanced diet.

There is no specific clinical guideline for dark chocolate intake in people with fatty liver disease. As a general principle of moderation within a balanced diet, small portions of high-cocoa dark chocolate are unlikely to be harmful for most people, but no daily target should be inferred from the available evidence.

Choosing chocolate with a higher cocoa percentage (typically 70 per cent or above) tends to increase flavanol content relative to added sugar, though cocoa percentage alone is not a reliable guide to flavanol levels because processing methods matter considerably. Heavily processed or Dutch-processed (alkalised) cocoa undergoes a chemical treatment that substantially reduces flavanol content.^[7][8] Minimally processed dark chocolate is therefore preferable if the goal is to retain potential liver-supportive compounds. Calorie and macronutrient content varies between products; the UK CoFID (McCance and Widdowson) nutrient dataset provides reference values, and checking individual product labels is advisable. Dark chocolate is calorie-dense, and overconsumption can contribute to weight gain, which is one of the primary drivers of fatty liver disease.

People with type 2 diabetes, which frequently coexists with MASLD, should be mindful of carbohydrate content and discuss any dietary changes with their diabetes care team.

The claim that increased cocoa intake can affect the metabolism of medicines is not well evidenced for the amounts typically consumed as food, and this article does not make that assertion. If you take regular medicines and are considering significant dietary changes, speak to your GP or pharmacist.

People with advanced liver disease, including cirrhosis or significant fibrosis, should seek specific dietary guidance from a hepatologist or specialist dietitian before making changes to their diet. The British Dietetic Association (BDA) provides patient-facing resources on nutrition and liver disease.

Which foods and drinks support a healthy liver alongside dark chocolate?

A Mediterranean-style diet is the most evidence-supported dietary pattern for MASLD, with coffee, oily fish, leafy greens, olive oil and nuts all associated with liver benefit.

A Mediterranean-style diet is the most consistently supported dietary pattern for people with fatty liver disease, recommended in European clinical practice guidelines (EASL-EASD-EASO 2024) and aligned with NHS dietary advice.^[10] Dark chocolate can fit within this framework as an occasional treat rather than a cornerstone food. The Mediterranean diet emphasises vegetables, legumes, wholegrains, oily fish, olive oil and nuts, all of which provide anti-inflammatory nutrients and support healthy metabolic function.

Specific foods with evidence for liver benefit include:

• Coffee: Regular consumption of unsweetened coffee has been associated with reduced liver inflammation and a lower risk of fibrosis progression in several observational studies and systematic reviews.^[12] The British Liver Trust summarises this evidence for patients. The mechanism is not fully established, but antioxidant compounds and effects on liver enzymes are thought to be involved.

• Oily fish: Salmon, mackerel and sardines provide omega-3 fatty acids, which observational and trial data suggest may help reduce liver fat and inflammation in people with MASLD, though effect sizes in trials have been modest.^[11][12]

• Leafy green vegetables: Spinach, kale and broccoli are associated in observational studies with improved liver enzyme levels and reduced steatosis; they also provide fibre that supports gut health.

• Olive oil: Extra virgin olive oil contains oleocanthal and other polyphenols with anti-inflammatory properties and is a preferred fat source in liver-supportive diets.

• Nuts and seeds: Walnuts in particular have been associated with improved liver enzyme levels in people with MASLD in some trials, though evidence remains limited.^[12]

Most of the evidence for individual foods is observational or from small trials, so these associations should be interpreted cautiously rather than as proven causal effects.

Conversely, foods and drinks to limit or avoid include alcohol, ultra-processed foods, sugary drinks, refined carbohydrates and foods high in saturated fat. Fructose, found in high quantities in sweetened beverages and some processed foods, is particularly associated with liver fat accumulation and should be minimised. Staying well hydrated with water remains a simple but important part of overall liver health. The NHS Mediterranean diet page and BDA resources provide further practical guidance.

What else can you do to manage fatty liver disease in the UK?

NICE NG49 recommends weight loss of 7 to 10 per cent, at least 150 minutes of weekly physical activity, alcohol reduction and blood sugar control as the cornerstones of MASLD management.

Fatty liver disease is managed primarily through sustained lifestyle change. NICE guideline NG49 (NAFLD: assessment and management) supports weight loss, increased physical activity and dietary improvement as the cornerstones of treatment for MASLD.^[16] There is currently no medicine specifically licensed for MASLD in the UK, though several are under investigation in clinical trials; check with your GP or hepatologist for the most up-to-date position.^[18]

Key steps recommended within UK clinical practice include:

• Weight management: NICE NG49 indicates that losing 7 to 10 per cent of body weight can significantly reduce liver fat and inflammation. Even modest weight loss of 3 to 5 per cent may improve liver enzyme levels.

• Physical activity: Both aerobic exercise and resistance training have independent benefits for liver fat, separate from weight loss. NHS guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults.^[14]

• Alcohol reduction: Alcohol can accelerate liver damage in people with MASLD and should be kept within UK Chief Medical Officers' low-risk guidelines (no more than 14 units per week, spread across at least three days, with some alcohol-free days).^[15]

• Blood sugar and cholesterol management: Controlling type 2 diabetes and dyslipidaemia reduces the metabolic burden on the liver and slows disease progression.

UK clinical pathway: If you have been diagnosed with fatty liver disease, your GP may use a blood test called FIB-4 (which takes into account your age, liver enzyme levels and platelet count) to assess your risk of significant fibrosis. Age-adjusted cut-offs apply, and people with an indeterminate or high FIB-4 result may be referred for further assessment, which can include an enhanced liver fibrosis (ELF) test or specialist review. People with signs of significant fibrosis or cirrhosis are typically referred to a hepatologist. Your GP can advise on the appropriate pathway for your situation, in line with NICE NG49.

When to seek urgent help: Contact your GP promptly if you experience persistent fatigue, yellowing of the skin or eyes (jaundice), abdominal swelling, or easy bruising. Call 999 or go to your nearest A&E immediately if you experience vomiting blood, black or tarry stools, sudden severe confusion, or severe abdominal pain with difficulty breathing, as these may indicate serious complications requiring emergency care. For urgent but non-life-threatening concerns, NHS 111 can provide advice.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, which may be relevant for people whose fatty liver disease is linked to excess weight. Any prescription medicine would only be considered where clinically appropriate following a consultation.

Suspected adverse effects from any medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Understanding the evolving nomenclature of steatotic liver disease.
2. Global epidemiological patterns and disease burden of metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and alcohol-associated liver disease, and alcohol-associated liver disease.
3. EASL position paper on preclinical models of steatotic liver disease.
4. Cocoa flavonoids up-regulate antioxidant enzyme activity via the ERK1/2 pathway to protect against oxidative stress-induced apoptosis in HepG2 cells.
5. Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial.
6. Pathophysiology and therapeutic options for cirrhotic portal hypertension.
7. Impact of alkalization on the antioxidant and flavanol content of commercial cocoa powders.
8. The effect of cocoa alkalization on the non-volatile and volatile mood-enhancing compounds.
9. Functional changes induced by extrusion during cocoa alkalization.
10. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease.
11. Influence of lipid class used for omega-3 fatty acid supplementation on MASLD.
12. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of randomized controlled trials.
13. Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: a meta-analysis of randomized controlled trials.
14. Physical activity guidelines for adults aged 19 to 64.
15. Alcohol consumption: advice on low risk drinking.
16. NICE guideline NG49: Metabolic dysfunction-associated steatotic liver disease (NAFLD): assessment and management.
17. Non-alcoholic fatty liver disease (NAFLD).
18. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.

Frequently Asked Questions